Windtree Therapeutics

Windtree Therapeutics

Windtree Therapeutics, Inc. is a publicly traded biotechnology company listed on the Nasdaq under the ticker symbol WINT. The company was originally founded as Discovery Laboratories before rebranding to Windtree in 2016. Its focus lies in developing novel therapies for acute cardiovascular and pulmonary conditions, leveraging a deep pipeline of product candidates. The company's primary asset is istaroxime, a first-in-class dual mechanism agent being investigated for the treatment of acute cardiogenic shock. Clinical trials for istaroxime have shown potential to improve hemodynamic parameters in patients. Windtree also has a portfolio of surfactant therapies, including KL4 surfactant, designed for neonatal respiratory distress syndrome. The company has conducted research collaborations with institutions such as the University of Pennsylvania for preclinical work. Windtree is headquartered in Pennsylvania, with additional operations in Warrington, PA. The company's market capitalization was approximately $8.9 million as of mid-2026, reflecting its position as a small-cap public biotech. The firm operates with a lean structure, with fewer than 20 employees based on public filings. A key structural differentiator is Windtree's status as a publicly traded company with a clinical-stage pipeline, rather than a family office or private investment firm. This requires public disclosure of financials and clinical trial data through SEC filings, offering transparency to investors. The company's reliance on partnership and licensing deals for commercialization positions it as a focused drug developer.